Stuckey Ashley, Dizon Don S
The Warren Alpert Medical School of Brown University, The Program in Women's Oncology, Women & Infants' Hospital of Rhode Island, 101 Dudley Street, Providence, RI 02905, USA.
Womens Health (Lond). 2012 Jul;8(4):447-53. doi: 10.2217/whe.12.26.
Epithelial ovarian cancer is the leading cause of death in the developed world for women with gynecologic carcinomas. Despite the effectiveness of platinum salts and taxanes as primary treatments, approximately 80% of women will recur and for them prognosis with available treatments is poor. Of the novel mechanisms under active investigation, there is ample evidence to indicate that angiogenesis is important to the development, progression and poor prognosis of ovarian cancer. Novel treatments are therefore required. A number of agents are undergoing evaluation, including vascular disrupting agents, angiogenesis inhibitors, tyrosine kinase inhibitors and agents targeting the folate receptor. At present, Phase III data are only available for the VEGF-targeted monoclonal antibody, bevacizumab, and that has demonstrated a progression-free survival benefit when used in combination with first-line paclitaxel/carboplatin and continued as maintenance therapy. The strategy of inhibiting angiogenesis in ovarian cancer remains promising. However, other agents in development may point to other important targets in ovarian cancer.
上皮性卵巢癌是发达国家妇科癌症女性死亡的主要原因。尽管铂盐和紫杉烷作为主要治疗方法有效，但约80%的女性会复发，且现有治疗方法对她们的预后不佳。在正在积极研究的新机制中，有充分证据表明血管生成对卵巢癌的发生、发展和预后不良很重要。因此需要新的治疗方法。许多药物正在接受评估，包括血管破坏剂、血管生成抑制剂、酪氨酸激酶抑制剂和靶向叶酸受体的药物。目前，只有针对血管内皮生长因子（VEGF）的单克隆抗体贝伐单抗有Ⅲ期数据，且已证明其与一线紫杉醇/卡铂联合使用并持续作为维持治疗时可带来无进展生存获益。抑制卵巢癌血管生成的策略仍然很有前景。然而，其他正在研发的药物可能指向卵巢癌的其他重要靶点。
